Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...
Every RNA virus—from stomach bugs and influenza to measles and the common cold—has its own story to tell, with a unique ...
Moderna’s mRNA vaccine, combined with Merck’s immunotherapy Keytruda, succeeded in a late-stage trial for cancer, the ...
Investors betting against shares of Moderna faced record one-day losses on Wednesday as the biotech company's stock more ...
The study is ongoing, but interim results found the treatment, Intismeran, met both its primary target of reducing cancer ...
The late-stage melanoma trial with Merck’s Keytruda shows both lower recurrence and less spread, with no new safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results